DODa Young Oh

Da Young Oh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Da Young Oh has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lipid-sensing GPCRs in Cardiometabolic Diseases: Emerging Roles for GPR84

    by Chang Yeob Han, Da Young Oh

    Chang Yeob Han and Da Young Oh. KOBRA Reports 2026;2:. https://doi.org/10.64066/kobrareports.26.0015

  • Top Cited Papers
    Open Access

    Neuronal GPR75 deficiency protects against diet-induced obesity in a humanized mouse model

    by Xue-Nan Sun, Jan-Bernd Funcke, Chanmin Joung, Chao Li, Ayanna Cobb, Toshiharu Onodera, Joselin Velasco, May-Yun Wang, Patrick Joseph Antonellis, Christopher Mazzone, et al.

    GPR75, a G protein–coupled receptor implicated in human obesity through loss-of-function variants, has emerged as a promising regulator of energy and metabolic homeostasis. To dissect its tissue-specific functions, we generated a humanized floxed Gpr75 mouse model with conditional deletions in the brain and adipose tissue. Mice with brain-specific Gpr75 deletion using Nestin-Cre were resistant to diet-induced obesity, primarily through suppressed food intake and modest increases in energy expenditure. In contrast, adipocyte-specific deletion of Gpr75 had minimal effects on systemic metabolism but modestly enhanced mitochondrial oxygen consumption in brown adipose tissue under cold exposure. Gpr75 expression was up-regulated in key brain regions and down-regulated in white adipose tissue under high-fat diet conditions, supporting a predominant central role in metabolic adaptation. Histological and transcriptomic analyses further revealed depot-specific effects on adipocyte morphology and hepatic lipid accumulation in global knockouts. These findings position GPR75 as a critical regulator of central energy balance and provide a mechanistic framework for developing brain-targeted therapies against obesity.


  • Open Access

    Two decades of FFAR4 biology: From nutrient sensing to therapeutic targeting

    by Yulin Kong, DaYoung Oh, Shenglong Zhu


  • Adipogenin promotes the development of lipid droplets by binding a dodecameric seipin complex

    by Chao Li, Xue-Nan Sun, Jan-Bernd Funcke, Lauri Vanharanta, Xavier Prasanna, Kaitlynn Gov, Yan Li, Megan Virostek, Chanmin Joung, Nolwenn Joffin, et al.

    The microprotein adipogenin (Adig) is predominantly expressed in adipose tissues. Here, we found that Adig interacts with seipin to form a stable, rigid complex. We present the structure of the seipin-Adig complex at an overall resolution of ~3.0 angstroms. The structure revealed that mammalian seipin assembles into two distinct oligomeric forms: undecamers and dodecamers. Adig selectively bound to the dodecameric form and enhanced seipin assembly by bridging and stabilizing adjacent subunits. Functionally, this complex promoted lipid droplet development at both early and late stages. In transgenic mice, adipocyte-specific overexpression of Adig increased fat mass and enlarged lipid droplets, whereas Adig deletion disrupted triglyceride accumulation in brown adipose tissues. Thus, Adig can modulate lipid storage through its structural and functional interactions with seipin.


  • Open Access

    Leptin as a key driver for organ fibrogenesis

    by Xue-Nan Sun, Shiuhwei Chen, Shangang Zhao, Jan-Bernd Funcke, Megan Virostek, Line Pedersen, Chao Li, Chanmin Joung, Qian Lin, Yan Li, et al.

    Leptin, a hormone primarily secreted by adipocytes, regulates energy balance and systemic metabolism through its interaction with the leptin receptor (LEPR). Beyond these functions, leptin signaling has been implicated in the pathogenesis of tissue fibrosis. Here, we report the x-ray crystal structures of a leptin-neutralizing antibody (hLep3) in the unbound and leptin-bound states. The interaction of this antibody with leptin mimics the interaction of the LEPR with leptin, providing direct insights into the mechanism by which the antibody disrupts leptin signaling. We furthermore evaluate the therapeutic potential of neutralizing leptin with this antibody across distinct mouse models of fibrosis affecting the kidney, liver, lung, heart, and blood vessels. Leptin neutralization markedly inhibited fibrosis progression in all models. Mechanistically, suppression of leptin activity reduces pro-inflammatory and profibrotic processes, underscoring its therapeutic potential. These findings suggest that leptin signaling plays a vital role in tissue fibrosis and that treatment with a leptin-neutralizing antibody may be a promising therapeutic approach.


  • Open Access

    GPR84-mediated signal transduction affects metabolic function by promoting brown adipocyte activity

    by Xue-Nan Sun, Yu A. An, Vivian A. Paschoal, Camila O. de Souza, May-Yun Wang, Lavanya Vishvanath, Lorena M.A. Bueno, Ayanna S. Cobb, Joseph A. Nieto Carrion, Madison E. Ibe, et al.

    The G protein–coupled receptor 84 (GPR84), a medium-chain fatty acid receptor, has garnered attention because of its potential involvement in a range of metabolic conditions. However, the precise mechanisms underlying this effect remain elusive. Our study has shed light on the pivotal role of GPR84, revealing its robust expression and functional significance within brown adipose tissue (BAT). Mice lacking GPR84 exhibited increased lipid accumulation in BAT, rendering them more susceptible to cold exposure and displaying reduced BAT activity compared with their WT counterparts. Our in vitro experiments with primary brown adipocytes from GPR84-KO mice revealed diminished expression of thermogenic genes and reduced O2 consumption. Furthermore, the application of the GPR84 agonist 6-n-octylaminouracil (6-OAU) counteracted these effects, effectively reinstating the brown adipocyte activity. These compelling in vivo and in vitro findings converge to highlight mitochondrial dysfunction as the primary cause of BAT anomalies in GPR84-KO mice. The activation of GPR84 induced an increase in intracellular Ca2+ levels, which intricately influenced mitochondrial respiration. By modulating mitochondrial Ca2+ levels and respiration, GPR84 acts as a potent molecule involved in BAT activity. These findings suggest that GPR84 is a potential therapeutic target for invigorating BAT and ameliorating metabolic disorders.


  • Open Access

    GPR92 activation in islet macrophages controls β cell function in a diet-induced obesity model

    by Camila O. de Souza, Vivian A. Paschoal, Xuenan Sun, Lavanya Vishvanath, Qianbin Zhang, Mengle Shao, Toshiharu Onodera, Shiuhwei Chen, Nolwenn Joffin, Lorena M.A. Bueno, et al.

    The molecular mechanisms underlying obesity-induced increases in β cell mass and the resulting β cell dysfunction need to be elucidated further. Our study revealed that GPR92, expressed in islet macrophages, is modulated by dietary interventions in metabolic tissues. Therefore, we aimed to define the role of GPR92 in islet inflammation by using a high-fat diet–induced (HFD-induced) obese mouse model. GPR92-KO mice exhibited glucose intolerance and reduced insulin levels — despite the enlarged pancreatic islets — as well as increased islet macrophage content and inflammation level compared with WT mice. These results indicate that the lack of GPR92 in islet macrophages can cause β cell dysfunction, leading to disrupted glucose homeostasis. Alternatively, stimulation with the GPR92 agonist farnesyl pyrophosphate results in the inhibition of HFD-induced islet inflammation and increased insulin secretion in WT mice, but not in GPR92-KO mice. Thus, our study suggests that GPR92 can be a potential target to alleviate β cell dysfunction via the inhibition of islet inflammation associated with the progression of diabetes.


  • Open Access

    GPR84-Mediated Signal Transduction Promotes Brown Adipocyte Function

    by Xuenan Sun, Yu A. An, Vivian A. Paschoal, Camila O. de Souza, May-Yun Wang, Lavanya Vishvanath, Lorena Arango, Ayanna Cobb, Joseph A. Nieto Carrion, Harrison Kidd, et al.

    SUMMARY: G protein-coupled receptor 84 (GPR84), a medium-chain fatty acid receptor, may be involved in various metabolic conditions but the mechanism remains unclear. We found that GPR84 is highly expressed and functions in brown adipose tissue (BAT). GPR84 knockout mice exhibited increased adiposity and vulnerability to cold exposure after aging, along with an increased BAT lipid content and decreased BAT activation compared to wild-type control mice. In vitro , primary brown adipocytes from GPR84 knockout mice showed reduced expression of thermogenic genes and lower O 2 consumption. The GPR84 agonist 6-OAU reversed these effects and restored brown adipocyte activation. In vivo and in vitro results showed that BAT defects in GPR84 knockout mice were attributed to mitochondrial dysfunction. GPR84 activation greatly affected intracellular calcium efflux, further influencing mitochondrial respiration. GPR84 activates BAT by controlling the mitochondrial calcium content and respiration, suggesting a therapeutic target for activating BAT and treating metabolic diseases. HIGHLIGHTS: High expression of GPR84 in brown adipocytes is induced by cold stimulation. Aged GPR84 knockout mice exhibit brown adipose tissue defects under cold exposure. GPR84 knockout mice show reduced mitochondrial function of brown adipocytes. GPR84 activation improves brown adipocyte functions.

  • Open Access

    Metabolic Functions of G Protein-Coupled Receptors and β-Arrestin-Mediated Signaling Pathways in the Pathophysiology of Type 2 Diabetes and Obesity

    by Camila Oliveira de Souza, Xuenan Sun, Dayoung Oh

    Seven transmembrane receptors (7TMRs), often termed G protein-coupled receptors (GPCRs), are the most common target of therapeutic drugs used today. Many studies suggest that distinct members of the GPCR superfamily represent potential targets for the treatment of various metabolic disorders including obesity and type 2 diabetes (T2D). GPCRs typically activate different classes of heterotrimeric G proteins, which can be subgrouped into four major functional types: Gαs, Gαi, Gαq/11, and G12/13, in response to agonist binding. Accumulating evidence suggests that GPCRs can also initiate β-arrestin-dependent, G protein-independent signaling. Thus, the physiological outcome of activating a certain GPCR in a particular tissue may also be modulated by β-arrestin-dependent, but G protein-independent signaling pathways. In this review, we will focus on the role of G protein- and β-arrestin-dependent signaling pathways in the development of obesity and T2D-related metabolic disorders.


  • Mitochondrial metabolism is a key regulator of the fibro-inflammatory and adipogenic stromal subpopulations in white adipose tissue

    by Nolwenn Joffin, Vivian A. Paschoal, Christy M. Gliniak, Clair Crewe, Abdallah Elnwasany, Luke I. Szweda, Qianbin Zhang, Chelsea Hepler, Christine M. Kusminski, Ruth Gordillo, et al.